223 related articles for article (PubMed ID: 34556109)
1. Inhibitory effects of Lactobacillus casei Shirota against both Candida auris and Candida spp. isolates that cause vulvovaginal candidiasis and are resistant to antifungals.
Paniágua AL; Correia AF; Pereira LC; de Alencar BM; Silva FBA; Almeida RM; de Medeiros Nóbrega YK
BMC Complement Med Ther; 2021 Sep; 21(1):237. PubMed ID: 34556109
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antifungal activity of bovine lactoferrin-producing probiotic Lactobacillus casei in the murine model of vulvovaginal candidiasis.
Liao H; Liu S; Wang H; Su H; Liu Z
BMC Microbiol; 2019 Jan; 19(1):7. PubMed ID: 30621597
[TBL] [Abstract][Full Text] [Related]
3. Lactobacillus acidophilus, L. plantarum, L. rhamnosus, and L. reuteri Cell-Free Supernatants Inhibit Candida parapsilosis Pathogenic Potential upon Infection of Vaginal Epithelial Cells Monolayer and in a Transwell Coculture System
Spaggiari L; Sala A; Ardizzoni A; De Seta F; Singh DK; Gacser A; Blasi E; Pericolini E
Microbiol Spectr; 2022 Jun; 10(3):e0269621. PubMed ID: 35499353
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of vaginal
Takano T; Kudo H; Eguchi S; Matsumoto A; Oka K; Yamasaki Y; Takahashi M; Koshikawa T; Takemura H; Yamagishi Y; Mikamo H; Kunishima H
Front Cell Infect Microbiol; 2023; 13():1113401. PubMed ID: 37201113
[TBL] [Abstract][Full Text] [Related]
5. Phytolectin nanoconjugates in combination with standard antifungals curb multi-species biofilms and virulence of vulvovaginal candidiasis (VVC) causing Candida albicans and non-albicans Candida.
Senthilganesh J; Kuppusamy S; Durairajan R; Subramaniyan SB; Veerappan A; Paramasivam N
Med Mycol; 2022 Jan; 60(2):. PubMed ID: 34958385
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.
Kan S; Song N; Pang Q; Mei H; Zheng H; Li D; Cui F; Lv G; An R; Li P; Xiong Z; Fan S; Zhang M; Chen Y; Qiao Q; Liang X; Cui M; Li D; Liao Q; Li X; Liu W
Mycopathologia; 2023 Apr; 188(1-2):99-109. PubMed ID: 36378354
[TBL] [Abstract][Full Text] [Related]
7. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E
Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489
[TBL] [Abstract][Full Text] [Related]
8. Antifungal susceptibilities, in vitro production of virulence factors and activities of ceragenins against Candida spp. isolated from vulvovaginal candidiasis.
Hacioglu M; Guzel CB; Savage PB; Tan ASB
Med Mycol; 2019 Apr; 57(3):291-299. PubMed ID: 29846682
[TBL] [Abstract][Full Text] [Related]
9. Biofilms and vulvovaginal candidiasis.
Rodríguez-Cerdeira C; Gregorio MC; Molares-Vila A; López-Barcenas A; Fabbrocini G; Bardhi B; Sinani A; Sánchez-Blanco E; Arenas-Guzmán R; Hernandez-Castro R
Colloids Surf B Biointerfaces; 2019 Feb; 174():110-125. PubMed ID: 30447520
[TBL] [Abstract][Full Text] [Related]
10. Antifungal activity of cathelicidin peptides against planktonic and biofilm cultures of Candida species isolated from vaginal infections.
Scarsini M; Tomasinsig L; Arzese A; D'Este F; Oro D; Skerlavaj B
Peptides; 2015 Sep; 71():211-21. PubMed ID: 26238597
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of Lactobacillus rhamnosus and Lactobacillus casei on Candida biofilm of denture surface.
Song YG; Lee SH
Arch Oral Biol; 2017 Apr; 76():1-6. PubMed ID: 28063305
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates.
Waikhom SD; Afeke I; Kwawu GS; Mbroh HK; Osei GY; Louis B; Deku JG; Kasu ES; Mensah P; Agede CY; Dodoo C; Asiamah EA; Tampuori J; Korbuvi J; Opintan JA
BMC Pregnancy Childbirth; 2020 May; 20(1):266. PubMed ID: 32375724
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of the association of 2 probiotic strains formulated in a slow release vaginal product, in women affected by vulvovaginal candidiasis: a pilot study.
Vicariotto F; Del Piano M; Mogna L; Mogna G
J Clin Gastroenterol; 2012 Oct; 46 Suppl():S73-80. PubMed ID: 22955364
[TBL] [Abstract][Full Text] [Related]
14. Difference Between the Profiles Presented by Yeasts that Colonize the Vaginal Mucosa or Cause Primary or Recurrent Candidiasis.
Moreira D; Ruiz LS; Leite-Jr DP; Auler ME; Ramos RTB; Costa VT; Lara BR; Gasparetto A; Gandra RF; Melhem MSC; Paula CR
Mycopathologia; 2021 Jun; 186(3):411-421. PubMed ID: 34120275
[TBL] [Abstract][Full Text] [Related]
15. Bioactive compounds with antifungal activity against pathogens isolated from pregnant woman: Gallesia integrifolia (garlic wood) is a promising treatment for vulvovaginal candidiasis.
de Souza ANV; Faria MGI; da Rocha CE; Philippsen GS; Silva GCC; da Silva GR; Inumaro RS; Gonçalves JE; Gazim ZC; Wietzikoski S; Lívero FADR; Seixas FAV; Wietzikoski Lovato EC
J Ethnopharmacol; 2022 Sep; 295():115403. PubMed ID: 35643209
[TBL] [Abstract][Full Text] [Related]
16. Biosurfactant from vaginal Lactobacillus crispatus BC1 as a promising agent to interfere with Candida adhesion.
De Gregorio PR; Parolin C; Abruzzo A; Luppi B; Protti M; Mercolini L; Silva JA; Giordani B; Marangoni A; Nader-Macías MEF; Vitali B
Microb Cell Fact; 2020 Jun; 19(1):133. PubMed ID: 32552788
[TBL] [Abstract][Full Text] [Related]
17. Antifungal activity of analogues of antimicrobial peptides isolated from bee venoms against vulvovaginal Candida spp.
Kočendová J; Vaňková E; Volejníková A; Nešuta O; Buděšínský M; Socha O; Hájek M; Hadravová R; Čeřovský V
FEMS Yeast Res; 2019 May; 19(3):. PubMed ID: 30753486
[TBL] [Abstract][Full Text] [Related]
18. Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment.
Woodburn KW; Clemens LE; Jaynes J; Joubert LM; Botha A; Nazik H; Stevens DA
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451496
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis.
Boikov DA; Locke JB; James KD; Bartizal K; Sobel JD
J Antimicrob Chemother; 2017 May; 72(5):1355-1358. PubMed ID: 28158577
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility profile of 200 recent clinical isolates of Candida spp. to topical antifungal treatments of vulvovaginal candidiasis, the imidazoles and nystatin agents.
Choukri F; Benderdouche M; Sednaoui P
J Mycol Med; 2014 Dec; 24(4):303-7. PubMed ID: 25442913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
